Tazemetostat, although clinically approved for and potent in selected cancer entities predominantly characterized by canonical EZH2 activities, specifically blocks EZH2 histone methyltransferase activity, but does not interfere with EZH2 expression [79]. The gene discussed is PRDM9; the disease is cancer.